Miller M
J Clin Endocrinol Metab. 1980 Jun;50(6):1016-20. doi: 10.1210/jcem-50-6-1016.
Studies were carried out in normal human subjects to determine the effect of two narcotic antagonists, oxilorphan and butorphanol, on antidiuretic hormone (ADH) release. Oxilorphan given to eight subjects on ad libitum fluid intake resulted in a transient but significant increase in 24-h free water clearance and a decrease in urine osmolality. These changes were not accompanied by an increase in creatinine or solute excretion, and urinary ADH levels did not rise even though plasma osmolality rose significantly from 289.4 +/- 0.9 to 292.9 +/- 0.8 mosmol/kg. Treatment with oxilorphan did not interfere with the response to ADH infusion in water-loaded subjects. Both oxilorphan and butorphanol significantly elevated the plasma osmolality at which ADH release became evident after the infusion of hypertonic saline in water-loaded subjects. Oxilorphan suppressed urinary ADH excretion at the time of the osmotic threshold for ADH release in spite of the greater plasma osmolality. The data indicate that the narcotic antagonists are capable of inhibiting ADH release in man during ad libitum fluid intake and in response to an osmotic stimulus by elevating the osmotic threshold for ADH release. It is concluded that narcotic antagonist inhibition of endogenous opioid action provides further evidence supporting a role for the brain opiates in the normal regulation of neurohypophysial hormone release in man.
在正常人体受试者中开展了多项研究,以确定两种麻醉性拮抗剂奥昔洛芬和布托啡诺对抗利尿激素(ADH)释放的影响。给八名随意饮水的受试者服用奥昔洛芬后,24小时自由水清除率出现短暂但显著的增加,尿渗透压降低。这些变化并未伴随肌酐或溶质排泄增加,尽管血浆渗透压从289.4±0.9显著升至292.9±0.8 mosmol/kg,但尿ADH水平并未升高。在水负荷受试者中,奥昔洛芬治疗并未干扰对ADH输注的反应。在水负荷受试者输注高渗盐水后,奥昔洛芬和布托啡诺均显著提高了ADH释放明显时的血浆渗透压。尽管血浆渗透压更高,但在ADH释放的渗透阈值时,奥昔洛芬抑制了尿ADH排泄。数据表明,麻醉性拮抗剂能够在随意饮水期间以及通过提高ADH释放的渗透阈值来抑制人体对渗透刺激的ADH释放。得出的结论是,麻醉性拮抗剂对内源性阿片样物质作用的抑制提供了进一步的证据,支持脑内阿片类物质在人体神经垂体激素释放的正常调节中发挥作用。